CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR
The present disclosure relates to a crystalline form and crystalline salts of s of N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)cyclopropanecarboxamide (Compound Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2A 5 receptor. The present discl...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BLACKBURN, ANTHONY C LIN, JUIN |
| description | The present disclosure relates to a crystalline form and crystalline salts of s of N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)cyclopropanecarboxamide (Compound Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2A 5 receptor. The present disclosure further relates to processes useful in the preparation of crystalline form and salts of Compound Ia and pharmaceutical compositions thereof.
La présente divulgation concerne une forme cristalline et des sels cristallins de N-(3-(4,6-diméthylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)éthoxy)phényl)cyclopropanecarboxamide (composé Ia) et des compositions pharmaceutiques de celui-ci qui modulent l'activité du récepteur 5 HT2A. La présente divulgation concerne en outre des processus utiles dans la préparation de la forme cristalline et des sels du composé Ia et des compositions pharmaceutiques de celui-ci. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3235907A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3235907A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3235907A13</originalsourceid><addsrcrecordid>eNqNjEEKwjAQRbtxIeod5gIFbRFxOaQTGkiTMpMWuipF4kq0UI_gwU3BA7j68P77f5t9FA8S0FrjCLTnRgBdBS17RSIkK4NQUyLUImMw3oHX0A5sGlOtq4rY9Knok90J6c4CCjS-6iwGz7Lq68M5rwMUCELsg3fGAZOiNin7bHOfHks8_HKXgaag6jzOrzEu83SLz_geFZZFeb4eL3gq_1C-DWQ85g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR</title><source>esp@cenet</source><creator>BLACKBURN, ANTHONY C ; LIN, JUIN</creator><creatorcontrib>BLACKBURN, ANTHONY C ; LIN, JUIN</creatorcontrib><description>The present disclosure relates to a crystalline form and crystalline salts of s of N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)cyclopropanecarboxamide (Compound Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2A 5 receptor. The present disclosure further relates to processes useful in the preparation of crystalline form and salts of Compound Ia and pharmaceutical compositions thereof.
La présente divulgation concerne une forme cristalline et des sels cristallins de N-(3-(4,6-diméthylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)éthoxy)phényl)cyclopropanecarboxamide (composé Ia) et des compositions pharmaceutiques de celui-ci qui modulent l'activité du récepteur 5 HT2A. La présente divulgation concerne en outre des processus utiles dans la préparation de la forme cristalline et des sels du composé Ia et des compositions pharmaceutiques de celui-ci.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230427&DB=EPODOC&CC=CA&NR=3235907A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230427&DB=EPODOC&CC=CA&NR=3235907A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BLACKBURN, ANTHONY C</creatorcontrib><creatorcontrib>LIN, JUIN</creatorcontrib><title>CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR</title><description>The present disclosure relates to a crystalline form and crystalline salts of s of N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)cyclopropanecarboxamide (Compound Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2A 5 receptor. The present disclosure further relates to processes useful in the preparation of crystalline form and salts of Compound Ia and pharmaceutical compositions thereof.
La présente divulgation concerne une forme cristalline et des sels cristallins de N-(3-(4,6-diméthylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)éthoxy)phényl)cyclopropanecarboxamide (composé Ia) et des compositions pharmaceutiques de celui-ci qui modulent l'activité du récepteur 5 HT2A. La présente divulgation concerne en outre des processus utiles dans la préparation de la forme cristalline et des sels du composé Ia et des compositions pharmaceutiques de celui-ci.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjEEKwjAQRbtxIeod5gIFbRFxOaQTGkiTMpMWuipF4kq0UI_gwU3BA7j68P77f5t9FA8S0FrjCLTnRgBdBS17RSIkK4NQUyLUImMw3oHX0A5sGlOtq4rY9Knok90J6c4CCjS-6iwGz7Lq68M5rwMUCELsg3fGAZOiNin7bHOfHks8_HKXgaag6jzOrzEu83SLz_geFZZFeb4eL3gq_1C-DWQ85g</recordid><startdate>20230427</startdate><enddate>20230427</enddate><creator>BLACKBURN, ANTHONY C</creator><creator>LIN, JUIN</creator><scope>EVB</scope></search><sort><creationdate>20230427</creationdate><title>CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR</title><author>BLACKBURN, ANTHONY C ; LIN, JUIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3235907A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BLACKBURN, ANTHONY C</creatorcontrib><creatorcontrib>LIN, JUIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BLACKBURN, ANTHONY C</au><au>LIN, JUIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR</title><date>2023-04-27</date><risdate>2023</risdate><abstract>The present disclosure relates to a crystalline form and crystalline salts of s of N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)cyclopropanecarboxamide (Compound Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2A 5 receptor. The present disclosure further relates to processes useful in the preparation of crystalline form and salts of Compound Ia and pharmaceutical compositions thereof.
La présente divulgation concerne une forme cristalline et des sels cristallins de N-(3-(4,6-diméthylpyrimidin-5-yl)-4-(2-(pyrrolidin-1-yl)éthoxy)phényl)cyclopropanecarboxamide (composé Ia) et des compositions pharmaceutiques de celui-ci qui modulent l'activité du récepteur 5 HT2A. La présente divulgation concerne en outre des processus utiles dans la préparation de la forme cristalline et des sels du composé Ia et des compositions pharmaceutiques de celui-ci.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3235907A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A42%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BLACKBURN,%20ANTHONY%20C&rft.date=2023-04-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3235907A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |